Lapatinib enhances the cytotoxic effects of doxorubicin in MCF-7 tumorspheres by inhibiting the drug efflux function of ABC transporters

Biomedicine and Pharmacotherapy

Volumn 72, Issue , 2015, Pages 37-43

  Chun, So Young ^a   Kwon, Yun Suk ^a   Nam, Kyung Soo ^a   Kim, Soyoung ^a  

^a Dongguk University College of Medicine   (South Korea)

Author keywords

ATP binding cassette (ABC) drug transporters; Chemoresistance; Lapatinib; MCF 7 breast cancer cells; Tumorsphere

Indexed keywords

ABC TRANSPORTER; BREAST CANCER RESISTANCE PROTEIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; LAPATINIB; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; PACLITAXEL; QUINAZOLINE DERIVATIVE;

ARTICLE; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; MCF 7 CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; CELL DEATH; DRUG EFFECTS; DRUG POTENTIATION; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MULTICELLULAR SPHEROID; PATHOLOGY; TRANSPORT AT THE CELLULAR LEVEL;

ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CELL DEATH; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SPHEROIDS, CELLULAR;

EID: 84930520744     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2015.03.009     Document Type: Article

References (31)

1. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. U. S. A. 2003, 100(7):3983-3988.
2. Beck B., Blanpain C. Unravelling cancer stem cell potential. Nat. Rev. Cancer 2013, 13(10):727-738.
3. Dean M. ABC transporters, drug resistance, and cancer stem cells. J. Mammary Gland Biol. Neoplasia 2009, 14(1):3-9.
4. Dean M., Fojo T., Bates S. Tumour stem cells and drug resistance. Nat. Rev. Cancer 2005, 5(4):275-284.
5. Higgins C.F. ABC transporters: from microorganisms to man. Annu. Rev. Cell Biol. 1992, 8:67-113.
6. Li L., Bhatia R. Stem cell quiescence. Clin. Cancer Res. 2011, 17(15):4936-4941.
7. Dontu G., Abdallah W.M., Foley J.M., Jackson K.W., Clarke M.F., Kawamura M.J., Wicha M.S. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 2003, 17(10):1253-1270.
8. Farnie G., Clarke R.B., Spence K., Pinnock N., Brennan K., Anderson N.G., Bundred N.J. Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways. J. Natl. Cancer Inst. 2007, 99(8):616-627.
9. Grimshaw M.J., Cooper L., Papazisis K., Coleman J.A., Bohnenkamp H.R., Chiapero-Stanke L., Taylor-Papadimitriou J., Burchell J.M. Mammosphere culture of metastatic breast cancer cells enriches for tumorigenic breast cancer cells. Breast Cancer Res. 2008, 10(3):R52.
10. Ponti D., Costa A., Zaffaroni N., Pratesi G., Petrangolini G., Coradini D., Pilotti S., Pierotti M.A., Daidone M.G. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res. 2005, 65(13):5506-5511.
11. Calvet C.Y., Andre F.M., Mir L.M. The culture of cancer cell lines as tumorspheres does not systematically result in cancer stem cell enrichment. PLoS ONE 2014, 9(2):e89644.
12. Pastrana E., Silva-Vargas V., Doetsch F. Eyes wide open: a critical review of sphere-formation as an assay for stem cells. Cell Stem Cell 2011, 8(5):486-498.
13. Shaw F.L., Harrison H., Spence K., Ablett M.P., Simoes B.M., Farnie G., Clarke R.B. A detailed mammosphere assay protocol for the quantification of breast stem cell activity. J. Mammary Gland Biol. Neoplasia 2012, 17(2):111-117.
14. Kim S., Alexander C.M. Tumorsphere assay provides more accurate prediction of in vivo responses to chemotherapeutics. Biotechnol. Lett. 2014, 36(3):481-488.
15. Uchida Y., Tanaka S., Aihara A., Adikrisna R., Yoshitake K., Matsumura S., Mitsunori Y., Murakata A., Noguchi N., Irie T., Kudo A., Nakamura N., Lai P.B., Arii S. Analogy between sphere forming ability and stemness of human hepatoma cells. Oncol. Rep. 2010, 24(5):1147-1151.
16. Kim S., Chun S.Y., Lee D.H., Lee K.S., Nam K.S. Mineral-enriched deep-sea water inhibits the metastatic potential of human breast cancer cell lines. Int. J. Oncol. 2013, 43(5):1691-1700.
17. Karukstis K.K., Thompson E.H., Whiles J.A., Rosenfeld R.J. Deciphering the fluorescence signature of daunomycin and doxorubicin. Biophys. Chem. 1998, 73(3):249-263.
18. Simon H.U., Haj-Yehia A., Levi-Schaffer F. Role of reactive oxygen species (ROS) in apoptosis induction. Apoptosis 2000, 5(5):415-418.
19. Gottesman M.M. Mechanisms of cancer drug resistance. Annu. Rev. Med. 2002, 53:615-627.
20. Dean M., Hamon Y., Chimini G. The human ATP-binding cassette (ABC) transporter superfamily. J. Lipid Res. 2001, 42(7):1007-1017.
21. Gottesman M.M., Fojo T., Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2002, 2(1):48-58.
22. Doyle L.A., Yang W., Abruzzo L.V., Krogmann T., Gao Y., Rishi A.K., Ross D.D. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 1998, 95(26):15665-15670.
23. Maliepaard M., van Gastelen M.A., de Jong L.A., Pluim D., van Waardenburg R.C., Ruevekamp-Helmers M.C., Floot B.G., Schellens J.H. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res. 1999, 59(18):4559-4563.
24. Hipfner D.R., Deeley R.G., Cole S.P. Structural, mechanistic and clinical aspects of MRP1. Biochim. Biophys. Acta 1999, 1461(2):359-376.
25. Dai C.L., Tiwari A.K., Wu C.P., Su X.D., Wang S.R., Liu D.G., Ashby C.R., Huang Y., Robey R.W., Liang Y.J., Chen L.M., Shi C.J., Ambudkar S.V., Chen Z.S., Fu L.W. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res. 2008, 68(19):7905-7914.
26. Perry J., Ghazaly E., Kitromilidou C., McGrowder E.H., Joel S., Powles T. A synergistic interaction between lapatinib and chemotherapy agents in a panel of cell lines is due to the inhibition of the efflux pump BCRP. Mol. Cancer Ther. 2010, 9(12):3322-3329.
27. Shukla S., Chen Z.S., Ambudkar S.V. Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance. Drug Resist. Updat. 2012, 15(1-2):70-80.
28. Grant S., Qiao L., Dent P. Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival. Front. Biosci. 2002, 7:d376-d389.
29. Normanno N., De Luca A., Bianco C., Strizzi L., Mancino M., Maiello M.R., Carotenuto A., De Feo G., Caponigro F., Salomon D.S. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006, 366(1):2-16.
30. Corkery B., Crown J., Clynes M., O'Donovan N. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. Ann. Oncol. 2009, 20(5):862-867.
31. Mukherjee A., Dhadda A.S., Shehata M., Chan S. Lapatinib: a tyrosine kinase inhibitor with a clinical role in breast cancer. Expert Opin. Pharmacother. 2007, 8(13):2189-2204.